Filing Flows › Kyntra Bio (KYNB) › How it makes money
How Kyntra Bio (KYNB) makes money
Kyntra Bio (KYNB) made $3.7M of revenue in the first quarter 2026 (Q1 2026), +36% from a year earlier. Drug Product Revenue brought in $3.5M (93%); Development and Other Revenue brought in $246K (7%).
Drawing the Sankey…
Revenue by segment, Q1 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Drug Product Revenue | $3.5M | 93.4% | — | +35% |
| Development and Other Revenue | $246K | 6.6% | — | +71% |
Where each dollar of revenue goes
| Line | Q1 2026 | % of revenue |
|---|---|---|
| Revenue | $3.7M | 100.0% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q1 2026 | $3.7M | +36% |
| Q4 2025 | $1.3M | -59% |
| Q3 2025 | $1.1M | -98% |
| Q2 2025 | $1.3M | +35% |
| Q1 2025 | $2.7M | -89% |
From Kyntra Bio's 10-Q filed May 12, 2026 (on EDGAR).
Questions
How does Kyntra Bio make money?
Kyntra Bio (KYNB) made $3.7M of revenue in the first quarter 2026 (Q1 2026), +36% from a year earlier. Drug Product Revenue brought in $3.5M (93%); Development and Other Revenue brought in $246K (7%).
What is Kyntra Bio's biggest business?
Drug Product Revenue: $3.5M in the first quarter 2026, 93% of revenue, +35% from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.